Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents

Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents. Related Content: Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

Episode metadata supplied by the publisher feed · Published Feb 6, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents

0:00 12:13

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Healthy Dialogue?

This episode is 12 minutes long.

When was this Healthy Dialogue episode published?

This episode was published on February 6, 2024.

Can I download this Healthy Dialogue episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!